A Theranostic and Precision Medicine Approach for Female-Specific Cancers

Prof. Rama Rao Malla is a faculty member of Department of Biochemistry and Bioinformatics, Institute of Science, GITAM (Deemed to be University), Visakhapatnam, Andhra Pradesh, India. Dr. Malla obtained his M.Sc. and Ph.D. in Biochemistry from Andhra University, Visakhapatnam, Andhra Pradesh, India. Dr. Malla did post-doctoral research in University of Illinois, College of Medicine, USA. The research focus of Dr. Malla is to explore tetraspanin CD151 as a therapeutic target and its miR candidates or exosomal CD151 as early diagnostic markers for TNBC. Dr. Malla also focusses on exploring the role of CD151 in tumor microenvironment and drug resistance mechanisms. He has published more than 85 research articles in peer reviewed international journals and presented over 100 abstracts in national and international conferences. Dr. Malla is author and co-author for more than 20 book chapters published by international publishers. He was an editorial board advisor and members for various international journals. He has received one research and one academic excellence award. Dr. Nagaraju obtained his MSc and his PhD, both in Biotechnology, from Sri Venkateswara University in Tirupati, Andhra Pradesh, India. He received his DSc from Berhampur University in Berhampur, Odisha, India. Dr. Nagaraju’s research focuses on translational projects related to gastrointestinal malignancies. He has published over 100 research papers in highly reputed international journals and has presented more than 50 abstracts at various national and international conferences. Dr. Nagaraju is author and editor of several published books for Elsevier and Springer Nature. He serves as editorial board member of several internationally recognized academic journals. Dr. Nagaraju has received several international awards including FAACC. He also holds memberships with the Association of Scientists of Indian Origin in America (ASIOA), the Society for Integrative and Comparative Biology (SICB), The Science Advisory Board, The RNA Society, The American Association for Clinical Chemistry (AACC) and the American Association of Cancer Research (AACR).

• 1. Overview of female specific cancer biology2. Circulating biomarkers for early diagnosis of FSCs3. Epigenetic biomarkers for the detection of FSCs4. Chemotherapy resistance mechanisms in FSCs5. Gene alterations with chemotherapy in FSCs6. Small molecule-targeted therapies for FSCs: success and failures7. Immunotherapies for FSCs8. Nanotechnology-based therapeutic approaches for FSCs: combining diagnosis and treatment9. Towards a personalized medicine approach for the treatment of FSCs